Positive News SentimentPositive NewsNASDAQ:MIRM Mirum Pharmaceuticals (MIRM) Stock Price, News & Analysis $51.83 -0.34 (-0.65%) Closing price 04:00 PM EasternExtended Trading$51.83 0.00 (0.00%) As of 04:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Mirum Pharmaceuticals Stock (NASDAQ:MIRM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Mirum Pharmaceuticals alerts:Sign Up Key Stats Today's Range$51.22▼$52.3350-Day Range$43.73▼$53.4652-Week Range$36.20▼$54.78Volume247,804 shsAverage Volume467,699 shsMarket Capitalization$2.57 billionP/E RatioN/ADividend YieldN/APrice Target$65.50Consensus RatingBuy Company Overview Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California. Read More Mirum Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks77th Percentile Overall ScoreMIRM MarketRank™: Mirum Pharmaceuticals scored higher than 77% of companies evaluated by MarketBeat, and ranked 242nd out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingMirum Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMirum Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.Read more about Mirum Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Mirum Pharmaceuticals are expected to grow in the coming year, from ($1.43) to ($0.70) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mirum Pharmaceuticals is -32.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mirum Pharmaceuticals is -32.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMirum Pharmaceuticals has a P/B Ratio of 11.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Mirum Pharmaceuticals' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.35% of the float of Mirum Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverMirum Pharmaceuticals has a short interest ratio ("days to cover") of 14.9, which indicates bearish sentiment.Change versus previous monthShort interest in Mirum Pharmaceuticals has recently increased by 4.66%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMirum Pharmaceuticals does not currently pay a dividend.Dividend GrowthMirum Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG4.2 / 5Environmental Score-1.69 Percentage of Shares Shorted15.35% of the float of Mirum Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverMirum Pharmaceuticals has a short interest ratio ("days to cover") of 14.9, which indicates bearish sentiment.Change versus previous monthShort interest in Mirum Pharmaceuticals has recently increased by 4.66%, indicating that investor sentiment is decreasing. News and Social Media3.2 / 5News Sentiment1.69 News SentimentMirum Pharmaceuticals has a news sentiment score of 1.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.06 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Mirum Pharmaceuticals this week, compared to 5 articles on an average week.Search InterestOnly 2 people have searched for MIRM on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows1 people have added Mirum Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Mirum Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $50,624.00 in company stock.Percentage Held by Insiders14.36% of the stock of Mirum Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Mirum Pharmaceuticals' insider trading history. Receive MIRM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mirum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address MIRM Stock News HeadlinesJolanda Howe Sells 477 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) StockJuly 4, 2025 | insidertrades.comMirum Pharmaceuticals price target raised to $76 from $68 at Evercore ISIJuly 12, 2025 | msn.comGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.July 25 at 2:00 AM | Stansberry Research (Ad)Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 10, 2025 | businesswire.comLiver Drug Stock Rockets 236% Amid FDA Approval As Sales Accelerate; Funds Load UpJune 17, 2025 | msn.comMirum Pharmaceuticals Inc.June 11, 2025 | barrons.comMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 10, 2025 | businesswire.comMirum Pharmaceuticals’ SWOT analysis: rare disease stock shows growth potentialMay 27, 2025 | investing.comSee More Headlines MIRM Stock Analysis - Frequently Asked Questions How have MIRM shares performed this year? Mirum Pharmaceuticals' stock was trading at $41.35 at the start of the year. Since then, MIRM shares have increased by 25.3% and is now trading at $51.83. How were Mirum Pharmaceuticals' earnings last quarter? Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) announced its quarterly earnings results on Wednesday, May, 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.05. The firm's revenue was up 61.2% on a year-over-year basis. Read the conference call transcript. When did Mirum Pharmaceuticals IPO? Mirum Pharmaceuticals (MIRM) raised $75 million in an initial public offering (IPO) on Thursday, July 18th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Evercore ISI and Guggenheim Securities served as the underwriters for the IPO and Raymond James and Roth Capital Partners were co-managers. Who are Mirum Pharmaceuticals' major shareholders? Top institutional shareholders of Mirum Pharmaceuticals include Atle Fund Management AB (0.22%), Secure Asset Management LLC (0.10%), Knights of Columbus Asset Advisors LLC (0.04%) and Oak Ridge Investments LLC (0.04%). Insiders that own company stock include Niall O'donnell, Patrick J Heron, Christopher Peetz, Lara Longpre, Pamela Vig, Peter Radovich, Eric Bjerkholt, Joanne Quan, Jolanda Howe, Saira Ramasastry and Michael G Grey. View institutional ownership trends. How do I buy shares of Mirum Pharmaceuticals? Shares of MIRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Mirum Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Mirum Pharmaceuticals investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities () and Sterne Agee CRT (). Company Calendar Last Earnings5/14/2025Today7/25/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MIRM CIK1759425 Webmirumpharma.com Phone(650) 667-4085FaxN/AEmployees140Year FoundedN/APrice Target and Rating Average Price Target for Mirum Pharmaceuticals$65.50 High Price Target$77.00 Low Price Target$49.00 Potential Upside/Downside+26.4%Consensus RatingBuy Rating Score (0-4)3.13 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($1.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$87.94 million Net Margins-20.39% Pretax Margin-20.01% Return on Equity-33.63% Return on Assets-11.50% Debt Debt-to-Equity Ratio1.32 Current Ratio3.22 Quick Ratio3.04 Sales & Book Value Annual Sales$336.89 million Price / Sales7.62 Cash FlowN/A Price / Cash FlowN/A Book Value$4.70 per share Price / Book11.03Miscellaneous Outstanding Shares49,530,000Free Float42,422,000Market Cap$2.57 billion OptionableOptionable Beta0.97 The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:MIRM) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mirum Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mirum Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.